News

Kazia Therapeutics has re-entered investor discussions following a favorable analyst initiation that assigned a Buy rating and a $25 price target. The optimism is centered on paxalisib, the company’s lead oncology candidate, and expectations for multiple upcoming catalysts over the next two years.

Aligos Therapeutics has delivered a meaningful operational and regulatory update for its chronic hepatitis B virus program. The company announced that the independent Data Safety Monitoring Board recommended continuation of the Phase 2 B-SUPREME study, while also endorsing expansion of a key patient cohort.

Immutep has moved back into focus after announcing a meaningful regulatory milestone for its lead immunotherapy candidate. The company received U.S. Food and Drug Administration Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, adding momentum to its oncology development strategy.

Clearmind Medicine has completed a financing transaction that quickly transitioned from debt issuance into equity conversion. The company issued $1.75 million in convertible promissory notes and received $1.58 million in cash proceeds, before the full principal amount was converted into shares by CLA Investors.

Precision BioSciences has taken another operational step forward in the development of PBGENE-HBV, its investigational gene-editing therapy for chronic hepatitis B. The company announced Clinical Trial Application approval to expand the global ELIMINATE-B study into France and Romania.

Arbutus Biopharma has received an important regulatory milestone after the U.S. Food and Drug Administration granted Fast Track designation to imdusiran for chronic hepatitis B.

Allogene Therapeutics has announced a substantial equity financing aimed at reinforcing its balance sheet and supporting continued advancement of its allogeneic CAR-T cell therapy pipeline.